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Abstract
No unmeasured confounding is often assumed in estimating treatment effects in
observational data when using approaches such as propensity scores and inverse proba-
bility weighting. However, in many such studies due to the limitation of the databases,
collected confounders are not exhaustive, and it is crucial to examine the extent to
which the resulting estimate is sensitive to the unmeasured confounders. We consider
this problem for survival and competing risks data. Due to the complexity of models
for such data, we adapt the simulated potential confounders approach of Carnegie et
al. (2016), which provides a general tool for sensitivity analysis due to unmeasured
confounding. More specifically, we specify one sensitivity parameter to quantify the
association between an unmeasured confounder and the treatment assignment, and
another set of parameters to quantify the association between the confounder and
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the time-to-event outcomes. By varying the magnitudes of the sensitivity parameters,
we estimate the treatment effect of interest using the stochastic EM and the EM al-
gorithms. We demonstrate the performance of our methods on simulated data, and
apply them to a comparative effectiveness study in inflammatory bowel disease (IBD).
Keywords Causal inference; Cox model; Expectation-Maximization algorithm; inverse
probability weighting (IPW); proportional hazards regression; regression adjustment; simu-
lated confounder; stochastic EM.
1 Introduction
When estimating the effect of a treatment or exposure on an outcome of interest, the gold-
standard approach is to conduct randomized control trials (RCT). In this setting, the poten-
tial outcomes are independent of treatment assignment, then the inference is straightforward.
However, in many cases, RCT is not feasible and the inference has to be drawn from ob-
servational studies. One of the major challenges in inferring causality from observational
studies is that the treatment selection mechanism is unknown and we have to rely on some
untestable assumptions. One widely used assumption is that there is no unobserved con-
founding, which means that the treatment assignment and the outcome are independent
conditional on the observed pre-treatment covariates. In the potential outcome framework
and under this assumption, there are several methods to adjust for the pre-treatment covari-
ates via the propensity, including matching, stratification, outcomes regression and inverse
probability weighting (IPW).1–5
Instead of believing that the no-unobserved-confounding assumption is satisfied, sensi-
tivity analysis offers an approach to assess the extent to which the inference is robust to
potential unmeasured confounders.2 Robins et al.6 argued that sensitivity analysis should
be conducted to examine how the inference varies if any untestable assumption is violated.
For example, an early sensitivity analysis was conducted in Cornfield et al.,7 who concluded
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that the association between cigarette smoking and lung cancer could be explained away only
if there existed a hidden bias associated with cigarette smoking that was at least as strong
as the association between cigarette use and lung cancer. Rosenbaum2 contains a nice intro-
duction describing the idea based on association between the unobserved confounder and the
treatment and between the unobserved confounder and the outcome. Analytical approaches
have been developed for simpler outcomes such as binary.8 Li et al.9 and Shen et al.10 con-
sidered sensitivity analysis methods for inverse probability weighted (IPW) estimators using
propensity scores that were gaining popularity in practice.11
Our motivation came from studies in inflammatory bowel disease (IBD). IBD is an um-
brella term for two conditions, ulcerative colitis (UC) and Crohns disease (CD), that are
characterized by chronic inflammation of the gastrointestinal tract.12 While randomized
clinical trials exist, these RCTs only represent 30% of patients seen and cared for in routine
practice. Furthermore, there are a growing number of treatment options, and head-to-head
comparisons are entirely lacking due to difficulty in performing these RCTs and the rapid
growth in treatment options. In order to compare the effectiveness between Vedolizumab
and tumor necrosis factor (TNF)-antagonist therapies for UC and CD patients, data were
collected between May 2014 and December 2017 from a North American based consortium
registry,13,14 which is a multi-center collaborative research group where outcomes are pooled
for consecutive UC and CD patients treated with biologics. Our primary endpoint is time to
clinical remission. Although data collection was rather exhaustive and accounted for most
known measurable confounders, treatment selection for IBD is known to be preference sen-
sitive and influenced by patient and provider perceptions, experiences, and understandings
of potential benefit and risk based on the data available to them, all of which are unmeasur-
able. We aim to assess to what extent our inference from the data is affected by potentially
unmeasured confounding.
Time to clinical remission is a survival endpoint; however, patients need time to achieve
this endpoint. Wide variability exists across centers, patients, and providers, for their prefer-
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ence to proceed with surgery while awaiting response to therapy. Therefore, surgery presents
a competing risk to clinical remission, in that surgery prevents the event of achieving clinical
remission. In Lukin et al.15 and Bohm et al.16 the authors considered propensity score meth-
ods with IPW as the primary approach to account for the observed covariates. However,
it is possible that there might be confounders not captured by the observed covariates. To
carry out sensitivity analysis for this type of complex outcomes, we found the simulated un-
observed confounder approach17 to be useful, since the analytical approaches seem difficult
to derive.
Under the simulated unobserved confounder setting we may consider two types of sensi-
tivity parameters, one describing the association between the unmeasured confounder and
the treatment assignment and the other describing the association between the unmeasured
confounder and the outcome. The interpretation of these parameters is relatively straightfor-
ward. To determine a plausible range of these sensitivity parameters, we take into consider-
ation the maximum observed association between a measured confounder and the treatment
assignment or the outcome, as well as the typical consideration of the strength of association
such as the odds ratio or hazard ratio for (say) a binary predictor, as we will see later in the
paper.
We organize our paper as follows. We describe our models in Section 2, including both
the survival models and the competing risks models. We consider estimation in Section 3,
using both the Expectation-Maximization (EM) algorithms and a stochastic EM algorithm.
In Section 4, we demonstrate the performance of our algorithms via simulations. We apply
our methods to the IBD data in Section 5. Finally, we conclude with discussion in Section 6.
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2 Models
2.1 Survival outcome
Denote T 0 a time-to-event outcome, Z a binary treatment assignment, and X a vector of
covariates. Due to possible right censoring, we observe T = min(T 0,C) and δ = I(T 0 ≤ C),
where C is the censoring time random variable, and I(⋅) the indicator function. We consider
U which represents the portion of unmeasured confounder(s) that is independent of X, and
will simply refer to U as the unmeasured confounder for the rest of the paper. We assume
U to be binary for ease of implementation, although other distributions are possible and
will be discussed later. Given Z, X and U , the hazard rate of T 0 is modeled using the Cox
proportional hazards (PH) regression:18
λ(t∣Z,X,U) = λ0(t) exp(τZ + β′X + ζU). (1)
In addition, we assume that given X and U , Z follows a generalized linear model; for
illustration purposes we assume a probit link below, although logistic would be an obvious
alternative:
P (Z = 1∣X,U) = Φ(X ′βz + ζzU), (2)
where Φ is the standard normal cumulative distribution function (CDF). In the above (ζz, ζ)
are sensitivity parameters, which quantify the relationships between the unobserved con-
founder and the treatment assignment and the outcome, respectively. Finally, we assume
that U ∼ Bernoulli(pi), and we set pi = 0.5.
Our goal is to simulate U given the observed T , δ, Z and X. We note that if the
parameters in the above are known, then
U ∣T, δ,Z,X ∼ Bernoulli(piT,δ,Z,X,U=1
piT,δ,Z,X
) , (3)
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where piT,δ,Z,X,U=u is the joint likelihood of (T, δ,Z,U = u) given X for u = 0,1, and piT,δ,Z,X =
piT,δ,Z,X,U=1 + piT,δ,Z,X,U=0. In particular,
piT,δ,Z,X,U = piU(1 − pi)1−U {Φ(X ′βz + ζzU)}Z {1 −Φ(X ′βz + ζzU)}1−Z
⋅{λ0(T )eτZ+β′X+ζU}δ exp{−Λ0(T ) ⋅ eτZ+β′X+ζU} . (4)
2.2 Competing risks
In the presence of competing risks, when an event occurs it may be one of m distinct
types of failures indexed by j = 1,2,⋯,m. Denote T 1,⋯, Tm the potential time-to-event
outcomes for the m types, and as before Z a binary treatment assignment, and X a vector
of covariates. We observe T = min(T 1,⋯, Tm,C), where C is the censoring time random
variable, δ = I(min(T 1,⋯, Tm) ≤ C) and J the type of failure if not censored. Again, we
consider an unmeasured binary confounder U that is independent of X. The cause-specific
hazard function19 for the j-th failure type is λj(t∣Z,X,U) = lim∆t→0 P(t ≤ T < t + ∆t, J =
j∣T ≥ t,Z,X,U)/∆t. We consider the proportional cause-specific hazards model (PCSH)
λj(t∣Z,X,U) = λj0(t) exp(τjZ + β′jX + ζjU), j = 1,2,⋯,m. (5)
As before we also assume that given X and U , Z follows a generalized linear model (2) with
a probit link. Then parallel to (4) we have
piT,δ,J,Z,X,U = piU(1 − pi)1−U {Φ(X ′βz + ζzU)}Z {1 −Φ(X ′βz + ζzU)}1−Z
⋅ m∏
j=1 {λj0(T )eτjZ+β′jX+ζjU}I(δ=1,J=j) exp{−Λj0(T ) ⋅ eτjZ+β′jX+ζjU} , (6)
where I(δ = 1, J = j) indicates whether subject had the event j. The posterior probability of
U is then obtained similar to (3). In general, if there are m distinct types of failures, then
there would be m + 1 sensitivity parameters, ζz, ζ1,⋯, ζm.
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3 Estimation
In order to simulation U given the observed data, we first need to estimate the unknown
parameters. Conditional on the unobserved U as well as Z and X, the likelihood function
of the survival outcome without competing risks is
L1 = n∏
i=1 λ(ti∣zi, xi, ui)δi exp{−Λ(ti∣zi, xi, ui)}= n∏
i=1 {λ0(ti)eτzi+β′xi+ζui}δi exp{−Λ0(ti)eτzi+β′xi+ζui} , (7)
Similarly, the likelihood function of the competing risks outcome given (Z,X,U) is
L1 = n∏
i=1
m∏
j=1 λj(ti∣zi, xi, ui)δij exp{−Λj(ti∣zi, xi, ui)}= n∏
i=1
m∏
j=1 {λj0(ti)eτjzi+β′jxi+ζjui}δij exp{−Λj0(ti)eτjzi+β′jxi+ζjui} , (8)
where δij ∶= I(δi = 1, Ji = j) indicates whether subject i had event j.
3.1 The EM algorithm
The EM algorithm20 is a commonly used approach to handle missing data, in this case U , in
the likelihood function. Let θ denote the unknown parameters, and yi the survival outcome
for subject i. The EM algorithm iterates between the E-steps and the M-steps that are
described below, where in the notation the covariate xi is suppressed which is always being
conditioned upon. The initial values can be set using the parameter estimates from the
regression models ignoring U . We note that the sensitivity parameters, as well as pi = 0.5,
are known.
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E-step
In the E-step we compute the conditional expectation of the log-likelihood of the complete
data (yi, zi, ui) given the observed data and the current parameter value θ˜. For the survival
outcome without competing risks, let
Q(θ) = E[l(θ;y,z,u)∣y,z, θ˜]
= E[l1(β, τ, λ0;y∣z,u)∣y,z, θ˜] +E[l2(βz;z∣u)∣y,z, θ˜] +E[l3(u)∣y,z, θ˜] (9)
∶= Q1(β, τ, λ0) +Q2(βz) +Q3,
where
Q1(β, τ, λ0) = n∑
i=1 [δi{logλ0(ti) + β′xi + ζE[ui∣yi, zi, θ˜] + τzi}−Λ0(ti) exp{β′xi + logE[eζui ∣yi, zi, θ˜] + τzi}] , (10)
Q2(βz) = n∑
i=1{ziE[log(Φ(x′iβz+ζzui))∣yi, zi, θ˜]+(1−zi)E[log(1−Φ(x′iβz+ζzui))∣yi, zi, θ˜]}, (11)
Q3 = n∑
i=1{logpiE[ui∣yi, zi, θ˜] + log(1 − pi)E[1 − ui∣yi, zi, θ˜]}. (12)
We note that Q3 is in fact not used in the M-step since it does not involve unknown param-
eters. As described earlier, given the observed data, U follows Bernoulli (p˜ii) as in (3) where
p˜ii is calculated based on the current parameter value θ˜. So for any function h(ui) in (10)
and (11), we have E[h(ui)∣yi, zi, θ˜] = h(1)p˜ii + h(0)(1 − p˜ii).
For competing risks outcome, from (8) we see that the likelihood function is a product
of m likelihoods, one for each type of event with its own type specific parameters. The
corresponding Q1 function is then a sum of Q1j(βj, τj, λj0)’s, each having the same form asQ1(β, τ, λ0) above but with parameters βj, τj, λj0 and data for the event type j instead.
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M-step
From (9) it is clear that in the M-step we can update (β, τ, λ0) and βz separately. In order
to maximize Q1, we note that it has the same form as the log-likelihood in a Cox regression
model with known offset logE[eζui ∣yi, zi, θ˜], just like the Cox model with random effects.21
For competing risks again because Q1 is a sum of Q1j(βj, τj, λj0)’s for j = 1, ...,m, each set
of parameters βj, τj, λj0 is updated separately using the Cox model software with offsets, the
same way as a single survival outcome.
To maximize Q2, we have
Q2(βz) = n∑
i=1 (zi [log{Φ(x′iβz + ζz)}p˜ii + log{Φ(x′iβz)}(1 − p˜ii)]+(1 − zi) [log{1 −Φ(x′iβz + ζz)}p˜ii + log{1 −Φ(x′iβz)}(1 − p˜ii)]) . (13)
This function can be maximized using the R function ‘optim’.
Variance estimation
As in typical nonparametric maximum likelihood inference under semiparametric models, the
variance-covariance matrix of θˆ is estimated by the inverse of a discrete observed information
matrix I(θˆ) following the EM algorithm, which is given by Louis’ formula22 based on missing
information principle:
I(θ) = E[−l¨(θ;y,z,u)∣y,z, θ] −E[s(θ;y,z,u)s(θ;y,z,u)′∣y,z, θ], (14)
where l¨ and s denote the second and first derivatives of l with respect to θ. The components
of l¨ and s are given in the Appendix.
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3.2 The Stochastic EM algorithm
Instead of the EM algorithm described above, the stochastic EM algorithm was used in
Carnegie et al.17, we think primarily due to its ease of implementation for practitioners as
well as intuitive appeal. It is similar to a Monte Carlo EM (MCEM) but in the E-steps only
a single U is drawn from the conditional distribution of U given the observed data, so that in
the M-steps the parameters are updated using that single sample of U as if it were observed.
A typical MCEM would otherwise draw many samples of U in order to approximate the
conditional expectations in the E-steps. The E- and M-steps are as described above for the
models that we consider in this paper, for both survival and competing risks outcomes.
At the convergence of the stochastic EM algorithm, in order to obtain a more accurate
estimate the E- and M-steps are repeated K times, and the final estimate of the treatment
effect on the survival outcome is τˆ = ∑Kk=1 τˆk/K, with the corresponding standard error
σˆτˆ = ¿ÁÁÀ 1
K
K∑
k=1 σˆ2τˆk + 1K − 1 K∑k=1(τˆk − τˆ)2, (15)
where σˆ2τˆk is estimated variance of τˆk pretending that the singly sampled Uk is observed. For
competing risks we have similarly for type j event τˆj = ∑Kk=1 τˆjk/K, and the corresponding
standard error is obtained using (15) with τˆk replaced by τˆjk and τˆ replaced by τˆj.
Nielsen et al.23 studied the asymptotic behavior of the stochastic EM algorithm, and
showed that under certain assumptions it is root-n consistent but not fully efficient. We
show in our data analysis that it can be naturally adapted to the IPW approach and obtain
inferential results in sensitivity analysis.
4 Simulations
We conducted simulation studies to investigate the performance of the EM as well as the
stochastic EM algorithms, as compared to the estimation of the treatment effect using the
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true confounder U with the given sensitivity parameters. For both survival and competing
risks outcomes, we set sample size n = 1,000, U ∼ Bernoulli(0.5), and two independent
covariates X1 ∼ N(0,1), X2 ∼ N(1,1) with βz = (0.25,−0.25)′ in (2). The number of EM
or stochastic EM steps was set to 20 (see Figure 6 and related discussion below), and true
sensitivity parameter values were used in fitting the models. The final estimates from the
stochastic EM were obtained by averaging over K = 40 estimates to reduce the variability.
For each case we show the results of 200 simulation runs.
4.1 Survival outcome
To simulate survival outcomes under model (1), we set λ0(t) = 1, β = (0.5,−1)′ and τ = 1. In
addition, we set censoring times C ∼ Uniform(1, 2) which led to between 25∼60% censoring,
depending on the combinations of the parameter values.
We run simulations over each combination of ζz ∈ {0,1,2} and ζ ∈ {−2,−1,0,1,2}. The
results of the simulation are reported in Table 1 and Figure 1. From Figure 1 it is clear
that ignoring U led to bias in the estimated treatment effect as long as ζ ≠ 0; this bias also
increases with the magnitude of ζ as well as the magnitude of ζz. On the other hand, both the
stochastic EM and the EM algorithm gave good estimates of the treatment effect compared
with the estimates using the true U ’s. Closer comparison of the results in Table 1 shows that
the EM algorithm gave more accurate estimates than the stochastic EM algorithm, both in
terms of generally less bias and smaller variances.
4.2 Competing risks outcomes
To simulate competing risks outcomes, we followed the approach designed in Beyersmann et
al.24. We assumed that m = 2, the baseline hazard functions for type 1 and type 2 failures
to be λ10(t) = λ20(t) = 1, and β1 = (0.5,−1)′, τ1 = 1, β2 = (−0.5,0.2)′, τ2 = −1 in model (5).
We then simulated the survival times with all-causes hazard λ = λ1+λ2, and the cause J was
generated from Bernoulli trials with P (J = 1∣Z,X,U) = λ1/(λ1 + λ2). We also set censoring
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times C ∼ Uniform(0.3, 0.7).
Similarly as the survival model, we first ran simulations over each combination of ζz ∈{0,1,2} and ζ1 = ζ2 ∈ {−2,−1,0,1,2}. This gave about 20∼60% censoring, depending on
the combinations of the parameter values, and about equal numbers of type 1 and type
2 events. In a second scenario, we fixed ζ1 = 1 and ζ2 ∈ {−2,−1,0,1,2} as before, which
gave about 20∼40% censoring, and type 1/2 event rates between 40/20% and 30/50%, again
depending on the combinations of the parameter values. The results of experiments are
reported in Table 2 (Figure 2) - Table 5 (Figure 5). All results show that for each type of
failure, the estimated treatment effect by either the stochastic EM or the EM recovered the
true treatment effect quite well, while ignoring U induced a substantial bias. In particular,
Table 4 and Figure 4 show that varying ζ2 had a noticeable impact on the estimation of τ1,
i.e. unobserved confounding for type 2 failure had a noticeable impact on the estimation of
the treatment effect on type 1 failure.
Finally, we take a closer look at the EM and the stochastic EM algorithm in a single
run in Figure 6. It is seen that the EM sequence displays a much smoother line than the
stochastic EM sequence; and even at convergence, the stochastic EM sequence has quite
some fluctuation compared to the EM sequence.
5 Sensitivity analysis of the IBD data
5.1 Ulcerative colitis data
Ulcerative colitis (UC) is one type of IBD that occurs in the large intestine (colon) and
the rectum, which is characterized clinically by bloody diarrhea and urgency. We are inter-
ested in comparing the effectiveness between Vedolizumab and tumor necrosis factor (TNF)-
antagonist therapy for UC patients. The data was collected between May 2014 and Decem-
ber 2017 from the North American based consortium registry.13 In brief, a total of 719 (453
treated with Vedolizumab, 266 with TNF-antagonist) UC patients with a median follow-up
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of 12 months were included. We focus on the treatment effect of vedolizumab (Z = 1) versus
TNF-antagonist (Z = 0) on clinical remission, which is defined as resolution of diarrhea,
rectal bleeding and urgency. In the Vedolizumab group, 187 patients had clinical remission
and no one had surgery, while in the TNF-antagonist group, 100 patients had clinical remis-
sion and 3 patients had surgery. Since there were only 3 competing events of surgery, too
few to fit any model, we had to simply treat surgery as independent censoring and applied
our approach under the survival models (i.e. without competing risks) to approximate the
treatment effect of Vedolizumab.
In Lukin et al.15 the propensity score for each subject i, denoted PSi, was calculated using
the R package ‘twang’25 based on pre-treatment variables, including age, disease extent,
clinical disease severity, UC related hospitalization within the preceding 1-year, prior TNF-
antagonist exposure, baseline steroid dependency or refractoriness, concomitant steroid use,
and concomitant immunomodulator use. Though the above potential confounders were
considered, it is unknown if all confounders have been included. Hence, sensitivity analysis
is necessary for this data.
To be consistent with Lukin et al.15, here we consider a single covariate Xi = Φ−1(PSi)
in our models, as this quantity is more likely to be normally distributed than PSi. We then
assume that there is an unmeasured confounder U ∼ Bernoulli(0.5). To determine the range
for the sensitivity parameters, we take into consideration the observed association between
a measured confounder and the treatment assignment or the outcome, in this case all less
than one in absolute value in terms of log odds ratio or log hazard ratio. In addition, a
probit coefficient on a binary variable (U) is likely to lie in [−2,2] in practice as suggested
in Carnegie et al.17. Similarly under the Cox PH model, the log hazard ratio of ±2 is very
substantial for a binary variable. Therefore, we focused on ζz ∈ [−2,2] and ζ ∈ [−2,2]. The
EM and stochastic EM algorithms were then applied as described in Section 3. The estimates
from the stochastic EM were obtained by averaging over K = 100 estimates. The sensitivity
analysis results are reported in Table 6 and Figure 7 panels (a) and (b).
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In the models without unmeasured confounding (ζz = ζ = 0), the estimates were βˆz
(SE) = 1.1002 (0.0926), βˆ (SE) = -0.3250 (0.0994), and τˆ (SE) = 0.5756 (0.1423), where
‘SE’ stands for standard error. We note that βˆz would have been exactly one if, instead of
‘twang’, probit regression had been used to fit the propensity score model. In addition, the
estimated treatment effect τˆ here was obtained by regression adjustment, compared to the
IPW estimate of Lukin.et al.15 (see sensitivity analysis for IPW below also). Nonetheless,
the estimated treatment effects are qualitatively consistent: Vedolizumab treated patients
were more likely to achieve clinical remission compared to TNF-antagonist therapy, with
hazard ratio (HR) = 1.7783 based on regression adjustment.
Figure 7(a) and (b) show that over a wide range of sensitivity parameters, the EM
and the stochastic EM gave very similar results. In the plots, the blue contours show the
sensitivity parameter values corresponding to the estimated treatment effect τˆ , and the red
curves correspond to where the absolute value of the t−statistic ∣t∣ = ∣τˆ/σˆτˆ ∣ = 1.96. Hence, any
combination of (ζz, ζ) in the region between two red curves in the upper right or lower left
quadrant leads to a non-significant estimated treatment effect at 0.05 level two-sided. Note
that except for very small random fluctuation in the stochastic EM results, the contours
and curves are symmetric about the origin (ζz, ζ) = (0,0), where the estimated τˆ = 0.5756 is
marked.
From the plots we see that in order to drive the estimated treatment effect to zero, (ζz, ζ)
will need to be close to (1.5, 1) or (1, 1.5), for example, compared to βˆz = 1.1002, βˆ = −0.3250
in model (1) above; such a very strong association between U and the survival outcome seems
unlikely. We also noted earlier that the observed association between a measured confounder
and the outcome were all less than one in absolute value in terms of log hazard ratio (the
largest being just under 0.6 in absolute value). Similarly the red curves in Figure 7 show
that in order to drive the estimate to be non-significant at 0.05 level, (ζz, ζ) will need to be
close to (1, 0.8), for example.
Finally, as IPW with PSi was the main statistical approach used in Lukin et al.15 to
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estimate the treatment effect, we also carried out sensitivity analysis for this approach. We
implemented this by combining the stochastic EM with IPW as follows. At convergence of the
algorithm we simulated Ui and estimated the propensity score P(Z = 1∣X,U) by regressing
Zi on Xi = Φ−1(PSi) and the simulated Ui, i = 1, ...n. Stabilized weights were obtained
and further trimmed to be within (0.1, 10) if necessary. The IPW approach was then
applied. The final estimates were also obtained by averaging over K = 100 estimates, with
the corresponding standard errors obtained using (15) where σˆ2τˆk was the sandwich variance
estimator following the IPW. The results are also reported in Table 6 and Figure 7(c). It
is seen that unlike the regression adjustment results above, where the estimated treatment
effect remained the same as long as ζ = 0, here instead the estimated treatment effect
remained the same as long as ζz = 0. We also note much larger standard errors when ∣ζz ∣ is
large, perhaps understandable as the treatment groups become more imbalanced. However,
similar to the regression adjustment results above, in order to drive the estimated treatment
effect to zero, (ζz, ζ) will need to be close to (1.5, 1) or (1, 1.5). On the other hand, the
estimated treatment effect may become non-significant at 0.05 level if (ζz, ζ) = (0.5,1) or(ζz, ζ) = (0.8,0.5).
5.2 Crohn’s disease data
Crohn’s disease (CD) is another type of IBD that can cause inflammation along anywhere
of the digestive tract. We are again interested in comparing the effectiveness between
Vedolizumab and tumor necrosis factor (TNF)-antagonist therapy for CD patients. The data
was collected between May 2014 and December 2017 from the North American based consor-
tium registry.14 A total of 1,242 patients were included (655 treated with Vedolizumab, 587
with TNF-antagonist therapy). The primary interest is the treatment effect of Vedolizumab
(Z = 1) versus (TNF)-antagonist (Z = 0) on clinical remission, which is defined as complete
resolution of CD-related symptoms. In the Vedolizumab group, 196 patients had clinical
remission and 9 had surgery, while in the TNF-antagonist group, 255 patients had clinical
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remission and 18 patients had surgery. Due to the presence of competing events, We ap-
plied our approach under the competing risks models to estimate the treatment effect of
Vedolizumab.
In Bohm et al.16, the propensity score for each subject i, denoted PSi, was calculated using
the R package ‘twang’25 based on pre-treatment variables, including prior TNF-antagonist
exposure and number of prior TNF-antagonists exposed, disease extent, history of fistulizing
disease, prior bowel surgery, disease phentyope, clinical disease severity, CD related hospital-
ization within the preceding 1-year, baseline steroid dependency or refractoriness, concomi-
tant steroid use, or concomitant immunomodulator use. It is unclear if all confounders have
been included, though. Hence, sensitivity analysis is also necessary for this data.
To be consistent with Bohm et al.16, we consider a single covariate Xi = Φ−1(PSi) in our
models and assume an the unmeasured confounder U ∼ Bernoulli(0.5). The range for the
sensitivity parameters is determined similarly as the UC data. We focus on ζz ∈ [−2,2] and
ζ1 ∈ [−2,2], and ζ2 ∈ {−2,0,2}. The EM and stochastic EM algorithms were then applied as
described in Section 3. The estimates from the stochastic EM were obtained by averaging
over K = 100 estimates. The sensitivity analysis results are reported in Table 7, Table 8,
Table 9 and Figure 8 panels (a) and (b).
In the models without unmeasured confounding (ζz = ζ1 = ζ2 = 0), the estimate of βz as
defined in model (2) is βˆz (SE) = 1.0631 (0.0513), the estimates of βj (j = 1,2) as defined
in model (5) are βˆ1 (SE) = −0.1664 (0.0562) and βˆ2 (SE) = −0.2601 (0.2401), and the
estimates of τj (j = 1,2) are τˆ1 (SE) = 0.0605 (0.1318) and τˆ2 (SE) = −0.0537 (0.5705).
If probit regression had been used to fit the propensity score model, βˆz would have been
exactly one. In addition, the estimated treatment effects τˆj (j = 1,2) here were obtained
by regression adjustment, compared to the IPW estimate of Bohm et al.16. Nonetheless,
the estimated treatment effects are consistent: there was no significant difference in time to
clinical remission between Vedolizumab and TNF-antagonist treated patients, with hazard
ratio (HR) = 1.0624 based on regression adjustment.
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Note that by our algorithms, ζ2 affects τˆ1 only through the conditional probability of
U as shown in (3). In this data, as the number of surgery is relatively small compared to
the number of clinical remission, the effect of ζ2 on τˆ1 is subtle (Table 7, Table 8, Table 9).
This is, of course, not necessarily true when the number of the competing risk events is
comparable to the number of events of interest.
Figure 8 (a) and (b) show that when ζ2 = 0, over a wide range of (ζz, ζ1), the EM and the
stochastic EM gave similar results. In the plots, the blue contours show the values of (ζz, ζ1)
corresponding to the estimated treatment effect τˆ1, and the red curves correspond to where
the absolute value of the t−statistic ∣t∣ = ∣τˆi/σˆτˆ1 ∣ = 1.96. Hence, any combination of (ζz, ζ1)
in the region surrounded by four red curves leads to a non-significant estimated treatment
effect at level 0.05 two-sided. Except for very small random fluctuation in the stochastic EM
results, the contours and curves are symmetric about the origin (ζz, ζ1) = (0,0), where the
estimated τˆ1 = 0.0605 is marked. In order to drive the estimated treatment effect to being
significant, given ζ2 = 0, (ζz, ζ1) will need to be close to (1,1) or (−0.8, 0.8), for example,
compared to βˆz = 1.0631 and βˆ1 = −0.1664 above; such a strong association between U and
the outcome seems unlikely in practice.
Finally, as IPW with PSi was the main statistical approach used in Bohm et al.16 to
estimate the treatment effect, we also carried out sensitivity analysis for this approach by
combing the stochastic EM with IPW as under the survival models. The final estimates
were also obtained by averaging over K = 100 estimates. The results are reported in Table 7,
Table 8, Table 9 and Figure 8(c). Similar to the regression adjustment results, in order to
drive the estimated treatment effect to significant, given ζ2 = 0, (ζz, ζ1) will need to be close
to (1, 1) or (-1, 1.5), which seems unlikely in practice.
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6 Discussion
In this paper we developed approaches to perform sensitivity analysis of the estimated treat-
ment effect with regard to unobserved confounding in observational studies with survival
or competing risks outcomes. The approaches we developed are based on models for sur-
vival or competing risks outcomes, which allow simulating the unobserved confounder given
the observed data. The sensitivity parameters reflect the association between the unob-
served confounder and the outcomes, as well as the association between the unobserved
confounder and the treatment assignments. The interpretation of these sensitivity param-
eters is straightforward, which leads to relative ease in choosing plausible ranges for them.
Simulation studies show that both the EM and the stochastic EM algorithm are able to
recover the true treatment effect if the correct sensitivity parameter values are used. The
EM algorithm is clearly optimal in theory,23 although the stochastic EM allows easy incor-
poration of IPW approaches for estimating treatment effects, which are commonly used in
practice and as we have illustrated in our data analysis.
For the distribution of the unobserved confounder we used binary 0, 1 with probability
0.5 each, which were recommended and used throughout the book by Rosenbaum.2 It is also
possible to incorporate normally distributed U , such as in Shen et al.10 and Xu et al.,26 in
which case the probit link in model (2) allows closed-form marginal propensity scores given X
after integrating out U . The Q1 part of the EM algorithm would be similar to that under the
proportional hazards mixed-effects model (PHMM) and Monte Carlo approximation would
be needed in the E-steps.21
Carnegie et al.17 discussed the advantages and disadvantages of using parametric ver-
sus nonparametric approaches in sensitivity analysis. Parametric approaches are typically
needed in order to simulate the unobserved confounder; in survival analysis however, the
outcome models are often semiparametric, allow flexibility in modeling in particular the
nuisance parameters. On the other hand, nonparametric bounds might be considered un-
der minimal assumptions in place of sensitivity analysis.27 However, such bounds can be
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very difficult to derive for complex outcomes like what we consider here in the presence of
right censoring, which is unlike in Shen et al.10 where it is possible to derive these bounds
for binary or continuous outcomes without censoring. Also evident in Shen et al.10 is that
parametric settings are often needed in order to aid in the interpretation of the sensitivity
parameters in the corresponding nonparametric settings, and extensive simulations have to
be conducted in order to determine sensible ranges for these sensitivity parameters.26
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APPENDIX
In the following we write out the components of l¨ and s for competing risks with j =
1, ...,m. For a single survival outcome without competing risks, we should simply take m = 1
and the corresponding parameters are the same as without the subscript j.
The components of s are:
∂l
∂βj
= n∑
i=1 xi{δij −Λj0(ti) exp(τjzi + β′jxi + ζjui)} (16)
∂l
∂τj
= n∑
i=1 zi{δij −Λj0(ti) exp(τjzi + β′jxi + ζjui)} (17)
∂l
∂λj0(ti) = 1λj0(ti) − ∑tk≥ti exp(τjzk + β′jxk + ζjuk) (18)
∂l
∂βz
= n∑
i=1 {zi φ(x′iβz + ζzui)Φ(x′iβz + ζzui) − (1 − zi) φ(x′iβz + ζzui)1 −Φ(x′iβz + ζzui)}xi (19)
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for j = 1,⋯,m. For the second derivatives,
∂2l
∂β2j
= − n∑
i=1 x⊗2i Λj0(ti) exp(τjzi + β′jxi + ζjui) (20)
∂2l
∂τ 2j
= − n∑
i=1 ziΛj0(ti) exp(τjzi + β′jxi + ζjui) (21)
∂2l
∂λj0(ti)2 = − 1λj0(ti)2 (22)
∂2l
∂βj∂τj
= − n∑
i=1 zixiΛj0(ti) exp(τjzi + β′jxi + ζjui) (23)
∂2l
∂βj∂λj0(ti) = − ∑tk≥ti xk exp(τjzk + β′jxk + ζjuk) (24)
∂2l
∂τj∂λj0(ti) = − ∑tk≥ti zk exp(τjzk + β′jxk + ζjuk) (25)
∂2l
∂βz2
= − n∑
i=1 φ(x′iβz + ζzui){ziφ(x′iβz + ζzui) + (x′iβz + ζzui)Φ(x′iβz + ζzui)Φ(x′iβz + ζzui)2+ (1 − zi)φ(x′iβz + ζzui) − (x′iβz + ζzui)(1 −Φ(x′iβz + ζzui))(1 −Φ(x′iβz + ζzui))2 }x⊗2i (26)
where a⊗2 = aa′ for a vector a, φ is the probability density function (pdf) of the standard
normal distribution, and all other off-diagonal elements are zeros. The computation of the
first term in (14) is similar to the computation in the E-step for different functions h(ui).
To calculate the second term in (14), we sample U from Bernoulli(p˜i) for 1,000 times after
convergence of the EM, and take the average of s(θ;y,z,u)s(θ;y,z,u)′ over the sampled
U ’s.
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Figure 1: Distributions of the estimated treatment effect (τˆ) for the simulated survival data.
ζz ∈ {0,1,2} on the horizontal label and ζ ∈ {−2,−1,0,1,2} on the vertical label. Each
boxplot displays τˆ from 200 simulations.
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Figure 2: Distributions of the estimated treatment effect on type 1 failures for the simulated
competing risks data. ζz ∈ {0,1,2} on the horizontal label and ζ1 = ζ2 ∈ {−2,−1,0,1,2} on
the vertical label. Each boxplot displays τˆ1 from 200 simulation runs.
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Figure 3: Distributions of the estimated treatment effect on type 2 failures for the simulated
competing risks data. ζz ∈ {0,1,2} on the horizontal label and ζ1 = ζ2 ∈ {−2,−1,0,1,2} on
the vertical label. Each boxplot displays τˆ2 from 200 simulations.
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Figure 4: Distributions of the estimated treatment effect on type 1 failures for the simulated
competing risks data. ζz ∈ {0,1,2} on the horizontal label, ζ1 = 1 and ζ2 ∈ {−2,−1,0,1,2} on
the vertical label. Each boxplot displays τˆ1 from 200 simulation runs.
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Figure 7: Sensitivity analysis results on the IBD for UC patients data for outcome clinical
remission. In all plots, the blue contours show the sensitivity parameter values corresponding
to the estimated treatment effect τˆ , and the red curves correspond to where the absolute
value of the t−statistic ∣t∣ = ∣τˆ/σˆτˆ ∣ = 1.96.
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Figure 8: Sensitivity analysis results on the IBD for CD patients data for outcome clinical
remission. In all plots, the blue contours show the values of (ζz, ζ1) corresponding to the
estimated treatment effect τˆ1, and the red curves correspond to where the absolute value of
the t−statistic ∣t∣ = ∣τˆi/σˆτˆ1 ∣ = 1.96.
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Table 1: Estimated treatment effect (standard deviation) for the simulated survival data
with τ = 1
Method ζz = 0 ζz = 1 ζz = 2
ζ = −2 True U 1.0171 (0.1244) 1.0108 (0.1171) 1.0033 (0.1166)EM 1.0216 (0.1496) 1.0101 (0.1469) 1.0015 (0.1297)
Sto EM 1.0257 (0.1502) 1.0132 (0.1468) 1.0066 (0.1296)
No U 0.7873 (0.1219) 0.1512 (0.1257) -0.2052 (0.1141)
ζ = −1 True U 1.0206 (0.1015) 1.0144 (0.1067) 1.0129 (0.1071)EM 1.0203 (0.1153) 1.0121 (0.1173) 1.0104 (0.1103)
Sto EM 1.0220 (0.1157) 1.0125 (0.1172) 1.0118 (0.1105)
No U 0.9310 (0.1068) 0.5664 (0.1109) 0.3524 (0.1068)
ζ = 0 True U 1.0159 (0.0868) 1.0124 (0.0996) 1.0095 (0.1035)EM 1.0159 (0.0868) 1.0124 (0.0996) 1.0095 (0.1035)
Sto EM 1.0159 (0.0868) 1.0124 (0.0996) 1.0095 (0.1035)
No U 1.0159 (0.0868) 1.0124 (0.0996) 1.0095 (0.1035)
ζ = 1 True U 1.0148 (0.0797) 1.0134 (0.0896) 1.0110 (0.1004)EM 1.0188 (0.0891) 1.0167 (0.0977) 1.0139 (0.1072)
Sto EM 1.0195 (0.0894) 1.0183 (0.0977) 1.0164 (0.1068)
No U 0.9059 (0.0802) 1.2601 (0.0878) 1.4993 (0.0971)
ζ = 2 True U 1.0133 (0.0768) 1.0164 (0.0875) 1.0154 (0.1031)EM 1.0226 (0.1047) 1.0260 (0.1122) 1.0263 (0.1218)
Sto EM 1.0225 (0.1052) 1.0271 (0.1127) 1.0303 (0.1228)
No U 0.6946 (0.0783) 1.2618 (0.0835) 1.6734 (0.0942)
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Table 2: Treatment effect estimate (standard deviation) on type 1 failures for the simulated
competing risks data with τ1 = 1
method ζz = 0 ζz = 1 ζz = 2
ζ1 = ζ2 = −2 True U 1.0150 (0.1428) 1.0293 (0.1603) 1.0305 (0.1644)EM 1.0154 (0.1767) 1.0357 (0.1801) 1.0354 (0.1831)StoEM 1.0180 (0.1788) 1.0390 (0.1825) 1.0428 (0.1844)
No U 0.9312 (0.1583) 0.3192 (0.1670) -0.0215 (0.1678)
ζ1 = ζ2 = −1 True U 1.0141 (0.1327) 1.0185 (0.1542) 1.0269 (0.1613)EM 1.0141 (0.1390) 1.0186 (0.1585) 1.0280 (0.1677)StoEM 1.0150 (0.1388) 1.0191 (0.1584) 1.0304 (0.1675)
No U 0.9817 (0.1339) 0.6243 (0.1536) 0.4260 (0.1635)
ζ1 = ζ2 = 0 True U 1.0153 (0.1212) 1.0258 (0.1329) 1.0317 (0.1593)EM 1.0153 (0.1212) 1.0258 (0.1329) 1.0317 (0.1593)StoEM 1.0153 (0.1212) 1.0258 (0.1329) 1.0317 (0.1593)
No U 1.0153 (0.1212) 1.0258 (0.1329) 1.0317 (0.1593)
ζ1 = ζ2 = 1 True U 1.0078 (0.1115) 1.0276 (0.1259) 1.0348 (0.1524)EM 1.0088 (0.1226) 1.0251 (0.1415) 1.0320 (0.1549)StoEM 1.0095 (0.1230) 1.0272 (0.1422) 1.0346 (0.1549)
No U 0.9745 (0.1130) 1.3518 (0.1319) 1.5750 (0.1470)
ζ1 = ζ2 = 2 True U 1.0064 (0.1094) 1.0263 (0.1238) 1.0345 (0.1570)EM 1.0022 (0.1370) 1.0174 (0.1600) 1.0266 (0.1645)StoEM 1.0031 (0.1369) 1.0230 (0.1615) 1.0345 (0.1652)
No U 0.9238 (0.1141) 1.5064 (0.1300) 1.8424 (0.1411)
33
Table 3: Treatment effect estimate (standard deviation) on type 2 failures for the simulated
competing risks data with τ2 = −1
method ζz = 0 ζz = 1 ζz = 2
ζ1 = ζ2 = −2 true U -1.0170 (0.1974) -0.9969 (0.1829) -0.9994 (0.1707)EM -1.0170 (0.2143) -0.9892 (0.1837) -0.9937 (0.1826)stoEM -1.0176 (0.2163) -0.9892 (0.1845) -0.9911 (0.1822)
no U -0.9893 (0.2002) -1.6139 (0.1713) -2.0409 (0.1709)
ζ1 = ζ2 = −1 true U -1.0236 (0.1702) -0.9996 (0.1484) -0.9964 (0.1469)EM -1.0231 (0.1772) -0.9945 (0.1518) -0.9940 (0.1517)stoEM -1.0233 (0.1774) -0.9951 (0.1518) -0.9936 (0.1515)
no U -1.0109 (0.1728) -1.3505 (0.1482) -1.5975 (0.1485)
ζ1 = ζ2 = 0 true U -1.0152 (0.1472) -0.9851 (0.1189) -0.9797 (0.1238)EM -1.0152 (0.1472) -0.9851 (0.1189) -0.9797 (0.1238)stoEM -1.0152 (0.1472) -0.9851 (0.1189) -0.9797 (0.1238)
no U -1.0152 (0.1472) -0.9851 (0.1189) -0.9797 (0.1238)
ζ1 = ζ2 = 1 true U -1.0088 (0.1316) -0.9886 (0.1019) -0.9836 (0.1097)EM -1.0108 (0.1423) -0.9950 (0.1109) -0.9887 (0.1115)stoEM -1.0110 (0.1434) -0.9953 (0.1117) -0.9883 (0.1114)
no U -0.9776 (0.1328) -0.5956 (0.1039) -0.3335 (0.1074)
ζ1 = ζ2 = 2 true U -1.0069 (0.1281) -0.9950 (0.0976) -0.9910 (0.1069)EM -1.0180 (0.1647) -1.0093 (0.1322) -1.0029 (0.1275)stoEM -1.0184 (0.1662) -1.0070 (0.1338) -0.9983 (0.1282)
no U -0.9075 (0.1313) -0.2871 (0.1038) 0.1522 (0.1050)
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Table 4: Treatment effect estimate (standard deviation) on type 1 failures for the simulated
competing risks data with τ1 = 1 and ζ1 = 1 fixed.
method ζz = 0 ζz = 1 ζz = 2
ζ2 = −2 true U 0.9971 (0.1011) 1.0187 (0.1163) 1.0271 (0.1505)EM 0.9963 (0.1093) 1.0174 (0.1320) 1.0263 (0.1545)stoEM 0.9971 (0.1101) 1.0189 (0.1320) 1.0282 (0.1549)
no U 0.8893 (0.0998) 1.2872 (0.1214) 1.5816 (0.1468)
ζ2 = −1 true U 1.0020 (0.1008) 1.0212 (0.1227) 1.0292 (0.1508)EM 1.0028 (0.1080) 1.0203 (0.1369) 1.0280 (0.1544)stoEM 1.0034 (0.1091) 1.0214 (0.1368) 1.0299 (0.1548)
no U 0.9023 (0.0992) 1.2980 (0.1264) 1.5844 (0.1465)
ζ2 = 0 true U 1.0033 (0.0966) 1.0271 (0.1183) 1.0326 (0.1481)EM 1.0040 (0.1045) 1.0258 (0.1338) 1.0305 (0.1507)stoEM 1.0050 (0.1045) 1.0275 (0.1338) 1.0325 (0.1510)
no U 0.9243 (0.0965) 1.3220 (0.1244) 1.5863 (0.1431)
ζ2 = 1 true U 1.0078 (0.1115) 1.0276 (0.1259) 1.0348 (0.1524)EM 1.0088 (0.1226) 1.0251 (0.1415) 1.0320 (0.1549)stoEM 1.0095 (0.1230) 1.0272 (0.1422) 1.0346 (0.1549)
no U 0.9745 (0.1130) 1.3518 (0.1319) 1.5750 (0.1470)
ζ2 = 2 true U 1.0148 (0.1231) 1.0245 (0.1402) 1.0301 (0.1592)EM 1.0135 (0.1353) 1.0195 (0.1506) 1.0255 (0.1609)stoEM 1.0146 (0.1356) 1.0223 (0.1511) 1.0295 (0.1615)
no U 1.0452 (0.1271) 1.3591 (0.1415) 1.5158 (0.1520)
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Table 5: Treatment effect estimate (standard deviation) on type 2 failures for the simulated
competing risks data with τ2 = −1 and ζ1 = 1 fixed.
method ζz = 0 ζz = 1 ζz = 2
ζ2 = −2 true U -1.0113 (0.1926) -1.0100 (0.1818) -1.0107 (0.1747)EM -1.0118 (0.2107) -0.9985 (0.1886) -1.0031 (0.1832)stoEM -1.0142 (0.2111) -1.0001 (0.1898) -1.0002 (0.1831)
no U -0.8715 (0.1996) -1.4541 (0.1786) -1.8513 (0.1766)
ζ2 = −1 true U -1.0224 (0.1803) -1.0066 (0.1556) -1.0082 (0.1537)EM -1.0222 (0.1887) -0.9995 (0.1546) -1.0038 (0.1567)stoEM -1.0227 (0.1888) -1.0001 (0.1549) -1.0035 (0.1568)
no U -0.9510 (0.1841) -1.2829 (0.1511) -1.5228 (0.1547)
ζ2 = 0 true U -1.0170 (0.1693) -1.0010 (0.1383) -0.9957 (0.1329)EM -1.0170 (0.1693) -1.0010 (0.1383) -0.9957 (0.1329)stoEM -1.0170 (0.1693) -1.0010 (0.1383) -0.9957 (0.1329)
no U -1.0170 (0.1693) -1.0010 (0.1383) -0.9957 (0.1329)
ζ2 = 1 true U -1.0088 (0.1316) -0.9886 (0.1019) -0.9836 (0.1097)EM -1.0108 (0.1423) -0.9950 (0.1109) -0.9887 (0.1115)stoEM -1.0110 (0.1434) -0.9953 (0.1117) -0.9883 (0.1114)
no U -0.9776 (0.1328) -0.5956 (0.1039) -0.3335 (0.1074)
ζ2 = 2 true U -1.0054 (0.1153) -0.9918 (0.0933) -0.9876 (0.0969)EM -1.0143 (0.1513) -1.0037 (0.1272) -0.9976 (0.1175)stoEM -1.0139 (0.1522) -1.0026 (0.1276) -0.9927 (0.1174)
no U -0.7921 (0.1136) -0.1505 (0.0981) 0.3065 (0.0977)
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